Across TCGA pan-cancer cohorts, ZNRF2P2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZNRF2P2 data layer compared with 22 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher ZNRF2P2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNRF2P2 expression acts as an unfavorable survival marker.
COAD, LUSC, and UCEC are the cancer types where ZNRF2P2 Mutation most reproducibly stratifies survival.